Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Accumulated Depreciation & Amortization (2016 - 2020)

Historic Accumulated Depreciation & Amortization for Neurocrine Biosciences (NBIX) over the last 10 years, with Q4 2020 value amounting to $41.7 million.

  • Neurocrine Biosciences' Accumulated Depreciation & Amortization rose 2410.71% to $41.7 million in Q4 2020 from the same period last year, while for Dec 2020 it was $41.7 million, marking a year-over-year increase of 2410.71%. This contributed to the annual value of $41.7 million for FY2020, which is 2410.71% up from last year.
  • According to the latest figures from Q4 2020, Neurocrine Biosciences' Accumulated Depreciation & Amortization is $41.7 million, which was up 2410.71% from $33.6 million recorded in Q4 2019.
  • Neurocrine Biosciences' 5-year Accumulated Depreciation & Amortization high stood at $41.7 million for Q4 2020, and its period low was $26.0 million during Q4 2016.
  • For the 5-year period, Neurocrine Biosciences' Accumulated Depreciation & Amortization averaged around $31.4 million, with its median value being $28.3 million (2018).
  • As far as peak fluctuations go, Neurocrine Biosciences' Accumulated Depreciation & Amortization plummeted by 339.15% in 2016, and later skyrocketed by 2410.71% in 2020.
  • Over the past 5 years, Neurocrine Biosciences' Accumulated Depreciation & Amortization (Quarter) stood at $26.0 million in 2016, then grew by 6.28% to $27.6 million in 2017, then grew by 2.51% to $28.3 million in 2018, then rose by 18.85% to $33.6 million in 2019, then increased by 24.11% to $41.7 million in 2020.
  • Its Accumulated Depreciation & Amortization stands at $41.7 million for Q4 2020, versus $33.6 million for Q4 2019 and $28.3 million for Q4 2018.